Drug Trial Radar · NCT00321672
Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy
Last checked: Nov 20, 2026Latest source record: Jun 14, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
494
Actual
Start
Jun 2006
Primary completion
Dec 2007
Study completion Dec 2007
Sponsor
- Lead sponsor
- NeurogesXIndustry
- Sponsor type
- Industry
- First posted
- May 4, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study was to assess the efficacy and safety of NGX-4010 applied for 30 or 60 minutes for the treatment of painful HIV-associated neuropathy.
Conditions
- Pain
- HIV Infections
- Peripheral Nervous System Diseases
Interventions
NGX-4010, 8% capsaicin patchDrug
Up to 4 NGX-4010 patches of 280 cm\^2 each were applied to the feet (2 per foot) for 60 minutes.
0.04% capsaicin patchDrug
Up to 4 control patches of 280 cm\^2 each were applied to the feet (2 per foot) for 60 minutes.
NGX-4010, 8% capsaicin patchDrug
Up to 4 NGX-4010 patches of 280 cm\^2 each were applied to the feet (2 per foot) for 30 minutes.
0.04% capsaicin patchDrug
Up to 4 control patches of 280 cm\^2 each were applied to the feet (2 per foot) for 30 minutes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Primary Measure of Efficacy Was the Percent Change in the "Average Pain for the Past 24 Hours" Numeric Pain Rating Scale (NPRS) Score From Baseline During Weeks 2 to 12.Time frame: Weeks 2-12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.